The Explorer Air II device is now approved for use with Pafolacianine during intraoperative fluorescence imaging. Credit: SurgVision / PRNewswire.

The US Food and Drug Administration (FDA) has granted 510(k) clearance to SurgVision’s Explorer Air II device for use with Pafolacianine during intraoperative fluorescence imaging.

Explorer Air II is claimed to be the first product based on SurgVision’s next-generation technology platform.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Marketed by On Target Laboratories under the brand name Cytalux, Pafolacianine is an optical imaging agent used in fluorescence-guided surgery.

Designed to meet the requirements of oncological intraoperative fluorescence imaging, the system will enable real-time imaging during surgery.

The company stated that the system’s prototype has been evaluated for different indications by academic centres.

According to SurgVision, the Explorer Air II can also attain high sensitivity and imaging fidelity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SurgVision CEO Stefan Schorling said: “We are very excited about this important milestone. Our goal is to make the Explorer Air II available to surgeons, supporting them in their mission to fight cancer.”

The Explorer Air II device previously received approval in the US, as well as a CE mark in the European Union (EU), for visual assessment of blood flow and tissue perfusion.

Part of Bracco Group, SurgVision is a medical technology firm that leverages imaging technologies to enhance outcomes and lower the cost of care.

SurgVision stated that its development pipeline aggregates highly sensitive imaging solutions to visualise tumours during surgical or interventional procedures in real-time, helping in the sensitive and precise detection of tumours.